new england journal of medicine tirzepatide In the SURMOUNT-1 trial (published in NEJM in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor Tirzepatide maintains weight loss in
Pay in 4 interest-free payments of $7.32 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10



















:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)






